Successful single-dose prophylaxis of Staphylococcus aureus foreign body infections in guinea pigs by fleroxacin.

Antimicrobial Agents and Chemotherapy
N BouchenakiD P Lew

Abstract

Single-dose administration of fleroxacin was evaluated as a means of preventing foreign body infection due to staphylococci. Tissue cages were implanted into guinea pigs and subsequently infected (100% rate) with 10(2) or more CFU of Staphylococcus aureus Wood 46. When a single dose of 30 mg of fleroxacin or vancomycin per kg of body weight was administered intraperitoneally, bactericidal levels of the antimicrobial agent were found in the tissue cage fluid after 3 h (when guinea pigs were inoculated with S. aureus) and during the next 24 h. Either fleroxacin or vancomycin successfully prevented experimental infection in all tissue cages challenged by 10(2) CFU of S. aureus Wood 46. When tissue cages were challenged with 10(4) CFU of S. aureus Wood 46, however, fleroxacin was more effective than vancomycin (P less than 0.05) in reducing colony counts below the detection limit of 10 CFU/ml in the inflammatory fluid of all tissue cages during the initial 48 h. In contrast to their initially different actions, the effects of the antibiotics were similar after 7 days, mostly because bacterial regrowth occurred more frequently in the fleroxacin-treated than in the vancomycin-treated tissue cages. These data show that experimental in...Continue Reading

References

Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·H AoyamaS Mitsuhashi
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·D J YoungsM R Keighley
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·M NakashimaH Uchida
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·E WeidekammD Dell
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·F SorgelP Muth
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·D J PohlodM M Somerville
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·A BauernfeindG Hörl
Feb 1, 1985·The Journal of Bone and Joint Surgery. American Volume·A G Gristina, J W Costerton
Jan 1, 1985·Scandinavian Journal of Infectious Diseases·W ZimmerliK Vosbeck
Apr 1, 1984·The Journal of Clinical Investigation·W ZimmerliF A Waldvogel
Oct 1, 1984·The Journal of Infectious Diseases·P VaudauxU E Nydegger
Oct 1, 1982·The Journal of Infectious Diseases·W ZimmerliU E Nydegger

❮ Previous
Next ❯

Citations

Jul 1, 1994·International Journal of Antimicrobial Agents·D Lew
Apr 1, 1991·Antimicrobial Agents and Chemotherapy·A F WidmerW Zimmerli
Apr 2, 2005·Journal of Materials Science. Materials in Medicine·A GanguliM H Grant
Oct 2, 2007·The Journal of Thoracic and Cardiovascular Surgery·Pierre-Yves LitzlerJean-Paul Bessou
Mar 26, 2004·Nature Reviews. Microbiology·Luanne Hall-StoodleyPaul Stoodley
May 21, 2021·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·O RobineauUNKNOWN from behalf of the G4 Bone and Joint infection study group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.